Market Place
Sourcing Support
Editas Medicine to Host Webinar Unveiling In Vivo Lead Candidate
28 Aug 2025 //
GLOBENEWSWIRE
Editas Medicine Reveals Q2 2025 Results and Updates
12 Aug 2025 //
GLOBENEWSWIRE
Editas Medicine Reports New In Vivo Data at ASGCT Meeting
14 May 2025 //
GLOBENEWSWIRE
Editas Medicine to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Editas Medicine To Report Q2 2024 Results
31 Jul 2024 //
GLOBENEWSWIRE
Editas Reports New Reni-Cel Data In Beta Thalassemia At EHA
14 Jun 2024 //
GLOBENEWSWIRE
Editas Reports New Reni-Cel Data In Sickle Cell At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
How Editas `dragged` new CSO over after 37 years at Biogen
10 May 2024 //
FIERCE BIOTECH
Editas Medicine Announces First Quarter 2024 Results and Business Updates
08 May 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results
28 Feb 2024 //
GLOBENEWSWIRE
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results
21 Feb 2024 //
GLOBENEWSWIRE
Editas Medicine to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
ASH: Editas shares data for mid-stage sickle cell disease asset
11 Dec 2023 //
FIERCE BIOTECH
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
03 Nov 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Third Quarter 2023 Results Conference Call
27 Oct 2023 //
GLOBENEWSWIRE
Editas Medicine Appointed Caren Deardorf as Chief Commercial Officer
25 Sep 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grants to New Chief Commercial Officer
25 Sep 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Upcoming Investor Events
30 Aug 2023 //
GLOBENEWSWIRE
Editas & Azzur Expand Partnership to Accelerate Editas Manufacturing Capabilities
27 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Second Quarter 2023 Results Conference Call
26 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
25 Jul 2023 //
GLOBENEWSWIRE
Editas Medicine Appoints Linda C. Burkly, Ph.D., as Chief Scientific Officer
24 Jul 2023 //
GLOBENEWSWIRE
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
20 Jun 2023 //
FOOL
Editas Medicine Announces Offering of Common Stock
14 Jun 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Pricing of Offering of Common Stock
14 Jun 2023 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
18 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces Appointment of Erick J. Lucera as CFO
16 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces First Quarter 2023 Results and Business Updates
05 May 2023 //
GLOBENEWSWIRE
Editas Medicine Announces First Quarter 2023 Results Conference Call
01 May 2023 //
GLOBENEWSWIRE
Editas Strengthens Board Of Directors With Appointment Of Chair & Director
13 Apr 2023 //
PRESS RELEASE
Editas Medicine Strengthens Board of Directors with Appointment of New Chair
13 Apr 2023 //
GLOBENEWSWIRE
Editas Announces Fourth Quarter and Full Year 2022 Results and Business Updates
22 Feb 2023 //
GLOBENEWSWIRE
Editas to Host Conference Discussing Fourth Quarter and Full Year 2022 Results
15 Feb 2023 //
GLOBENEWSWIRE
Editas touts skinnier pipeline after major shake-up
11 Jan 2023 //
FIERCE BIOTECH
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
09 Jan 2023 //
GLOBENEWSWIRE
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Editas reports early-stage data from two patients in sickle cell disease
06 Dec 2022 //
ENDPTS
Editas looks to bounce back with trickle of sickle cell data
06 Dec 2022 //
FIERCEBIOTECH
Editas Medicine Announces Positive Safety & Efficacy Data from Trial of EDIT-301
06 Dec 2022 //
GLOBENEWSWIRE
Editas Medicine to Host Virtual Event Clinical Data fromTrial of EDIT-301
01 Dec 2022 //
GLOBENEWSWIRE
Editas halts lead CRISPR program after efficacy data underwhelm
18 Nov 2022 //
ENDPTS
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept EDIT-101
17 Nov 2022 //
GLOBENEWSWIRE
Editas Medicine Announces Third Quarter 2022 Results And Business Updates
02 Nov 2022 //
PRESS RELEASE
Editas Announces Data Demonstrating EDIT-101 From Phase 1/2 BRILLIANCE Trial
01 Nov 2022 //
PRESS RELEASE
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results
26 Oct 2022 //
GLOBENEWSWIRE
Struggling Editas shops preclinical cancer pipeline during its big makeover
18 Oct 2022 //
ENDPTS
Editas Medicine Presents Preclinical Data on EDIT-103
13 Oct 2022 //
GLOBENEWSWIRE
Editas Medicine to Participate in Upcoming Investor Conferences
01 Sep 2022 //
GLOBENEWSWIRE
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
03 Aug 2022 //
GLOBENEWSWIRE
Editas Medicine Announces Clinical Achievements for EDIT-301 for SCD
27 Jul 2022 //
GLOBENEWSWIRE
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results
26 Jul 2022 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
20 Jul 2022 //
GLOBENEWSWIRE
Editas fills empty CMO role with Sanofi`s blood disorder chief
18 Jul 2022 //
FIERCEBIOTECH
Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer
18 Jul 2022 //
GLOBENEWSWIRE
Immatics, Editas Medicine Enter Research Collaboration and Licensing Agreement
07 Jun 2022 //
GLOBENEWSWIRE
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
06 Jun 2022 //
GLOBENEWSWIRE
Former Editas CEO Katrine Bosley goes the VC route
26 May 2022 //
ENDPTS
Editas Medicine Presents Data on SLEEK Gene Editing Technology
18 May 2022 //
GLOBENEWSWIRE
